TEVA

Teva- Pharmaceutical Industries Ltd. - ADR

Healthcare


Presented:06/13/2023
Price:$7.53
Cap:$8.44B
Current Price:$18.15
Cap:$20.56B

Presented

Date06/13/2023
Price$7.53
Market Cap$8.44B
Ent Value$29.51B
P/E RatioN/A
Book Value$7.02
Div Yield0%
Shares O/S1,120.37M
Ave Daily Vol13,057,095
Short IntN/A

Current

Price$18.15
Market Cap$20.56B
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Publicly traded companies mentioned herein: Eli Lilly & Co (LLY), Merck & Co Inc (MRK), Prometheus Biosciences Inc (RXDX), Teva Pharmaceutical Industries Ltd (TEVA)

Highlights

The presenter is long shares of Teva Pharmaceutical Industries Ltd (TEVA), which has underperformed significantly based on an implosion in the US generics industry, high leverage, litigation issues, and earnings misses. TEVA currently trades at $7.50 per share (6x consensus 2024 EBITDA), but most of its issues seem to be resolved and the base business has stabilized. This has left the base business fairly valued to slightly undervalued, with slight near-term upside from continued stabilization in the generics business plus execution on quarterly numbers. More significantly, he conservatively estimates ~$6 per share of pipeline value that is not priced into the stock, which could drive massive upside if data readouts are successful in 2H’24.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.